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Background and aims: Patients with familial hypercholesterolaemia (FH) have an elevated risk of coro-
nary heart disease (CHD). Here we compare changes in CHD mortality in patients with heterozygous (FH)
pre 1992, before lipid-lowering therapy with statins was used routinely, and in the periods 1992e2008
and 2008e2016.
Methods: 1903 Deﬁnite (DFH) and 1650 Possible (PFH) patients (51% women) aged 20e79 years,
recruited from 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2016
for 67,060 person-years. The CHD standardised mortality ratio (SMR) compared to the population in
England and Wales was calculated (with 95% Conﬁdence intervals).
Results: There were 585 deaths, including 252 from CHD. Overall, the observed 2.4-fold excess coronary
mortality for treated DFH post-1991 was signiﬁcantly higher than the 1.78 excess for PFH (35% 95% CI 3%
e76%). In patients with DFH and established coronary disease, there was a signiﬁcant excess coronary
mortality in all time periods, but in men it was reduced from a 4.83-fold excess (2.32e8.89) pre-1992 to
4.66 (3.46e6.14) in 1992e2008 and 2.51 (1.01e5.17) post-2008, while in women the corresponding
values were 7.23 (2.65e15.73), 4.42 (2.70e6.82) and 6.34 (2.06e14.81). Primary prevention in men with
DFH resulted in a progressive reduction in coronary mortality over the three time-periods, with no
excess mortality evident post-2008 (0.89 (0.29e2.08)), although in women the excess persisted (post-
2008 3.65 (1.75e6.72)).
Conclusions: The results conﬁrm the beneﬁt of statin treatment in reducing CHD mortality, but suggest
that FH patients with pre-existing CHD and women with FH may not be treated adequately.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Familial hypercholesterolemia (FH) is a common autosomal, BHF Laboratories, Rayne
versity Street, London, WC1E
c.uk, rmhaseh@ucl.ac.uk
r B.V. This is an open access articledominant disorder with the frequency of heterozygous FH being
estimated at 1 in 200e500 in most European populations [1e3].
Patients with FH are exposed to elevated low density lipoprotein
cholesterol (LDL-C) concentrations from birth and are at a higher
risk of Coronary Heart Disease (CHD) for any given LDL-C concen-
tration [4]. In the heterozygous condition the cumulative risk of
CHD by the age of 60 years without effective treatment is at least
50% in men and about 30% in women [5e7]. Before effective
treatment with lipid-lowering therapies such as statins becameunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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young adults aged 20e39 years, and about 4-fold for patients aged
40e59 years, but for those surviving through middle age, risk was
similar to the rates of CHD in the general population of England and
Wales [8,9].
In the UK, the Simon Broome FH register criteria [1,10] are used
to classify patients clinically into Deﬁnite FH (DFH) or Possible FH
(PFH) [1,10]. A diagnosis of DFH is made if the patient has low
density lipoprotein-cholesterol (LDL-C) level >4.9mmol/l and
tendon xanthoma (TX), while a diagnosis of PFH is made if the
patient has elevated cholesterol levels and a family history of hy-
percholesterolemia or early CHD. A diagnostic scoring tool has also
been developed by the Dutch Lipid Clinic Network (DLCN) where
each subject is given increasing points for increasing levels of un-
treated LDL-C, having TX and a family history of early CHD [10].
Those with a score >8 have Deﬁnite FH, those with a score between
5 and 8 have probable FH, 3e5 possible FH and a score below 3 are
designated as not-FH.
Mutations in three genes, the LDL-receptor gene (LDLR), the
gene coding for apolipoprotein B (APOB) and the gene encoding
protein convertase subtilisin/kexin 9 (PCSK9), are known to cause
FH [11]. In UK FH patients where a monogenic cause can be found,
approximately 93% carry a mutation in the LDLR gene, 5% in APOB
and 2% in PCSK9 [11]. Although other novel genes have been pro-
posed [12], none have yet been independently conﬁrmed. While in
DFH patients an FH-causing mutation can be identiﬁed in about
80% of subjects, this falls to only 20e30% in PFH patients [13]. In the
majority of patients with a clinical diagnosis of FH but with no
detectable mutation in any of the three common genes [14], it is
nowwidely accepted that there is a polygenic cause for their raised
LDL-C level [15,16].
Previous results from the UK Simon Broome Register have
shown that since the introduction and widespread use of statins,
the prognosis for patients with heterozygous FH has improved
markedly, with a reduction in coronary mortality of about a third.
Importantly, in patients with no known CHD at registration (i.e.,
primary prevention), all-cause mortality in treated FH patients is
signiﬁcantly lower than in the general population, mainly due to a
reduction of more than a third in the risk of fatal cancer. This was
probably because of the lower prevalence of cigarette smoking in
FH patients than in the general population [9,17], due to adherence
to advice to be physically active, make dietary changes, avoid
obesity and not to smoke cigarettes. The aim of this paper was to
extend our previous reports [9,17,18] by studying an enlarged
cohort of 3553 heterozygous patients followed for up to 36 years
until the end of 2016, bywhen the exposure had increased to 67,760
person-years. This has allowed us to examine the changes in
mortality compared with the general population of England and
Wales (Standardised Mortality Ratio, SMR) both before and after
the routine use of statins.
2. Materials and methods
The methods have been described previously [17]. The charac-
teristics of patients at registration were recorded on a standard
registration form. A fasting venous blood specimen taken at the
registration visit was used to determine serum total cholesterol,
triglycerides, and high density lipoprotein, and was measured by
the laboratories routinely used by the participating clinics. LDL-C
concentrations were calculated using the Friedewald formula
[19]. Registered patients were ﬂagged by the National Health Ser-
vice Central Registry and, in the event of death, a copy of the death
certiﬁcate was provided. The underlying cause of death was coded
by one investigator using the International Classiﬁcation of Disease
(ICD) 9th revision. All patients gave informed consent for inclusionin the Register. The study received approval from the local ethics
committee of each participating centre. Patients were classiﬁed as
having either Simon Broome (SB) Deﬁnite FH or Possible FH using
published criteria [10,17], or by using the Dutch Lipid Clinic
Network as described [10] and as shown in Supplementary
methods, with those with a score >8 having Deﬁnite FH, those with
a score between 5 and 8 Probable FH, with a score 3e5 as Possible
FH and those with a score below 3 designated as not-FH. Since the
majority of the subjects have not had DNA tests, this component
was not included in the score.
The analysis used a standard computer program for cohort
studies [20]. Person-years of risk were aggregated into 5-year age
groups and 5-year calendar periods and the expected number of
deaths from speciﬁed causes were estimated. A total of 571 subjects
were censored on reaching the age 80 years, and a further 50 pa-
tients who had emigrated were censored at the date of embarka-
tion. The expected number of deaths from CHD (ICD codes
4100e4149); stroke (4300e4389); non-coronary causes (10e4099
& 415e9999); cancers (1400e2089); site speciﬁc cancers, accidents
and violence (8000e9999); and total mortality were calculated by
applying the age and calendar-speciﬁc death rates for men and
women in the general population of England and Wales to the
person years accumulated by men and women in the cohort. The
standardised mortality ratio (SMR) was calculated from the ratio of
the number of deaths observed to those expected, and was
expressed as a percentage (SMR¼ 100 for the reference popula-
tion), and the exact 95% conﬁdence intervals were calculated. The
test of signiﬁcance used was a two-sided Poisson probability of
observing the number of deaths that occurred given the expected
number of deaths. A Cox-proportional hazard model was used to
identify univariate baseline characteristics that were signiﬁcantly
associated with CHD mortality, and a stepwise model used to
identify those that were independently associated using a signiﬁ-
cance level of 0.05 for entry to themodel and 0.10 for elimination. A
term for DFH/PFH was forced into the model to examine whether
the higher risk in DFH patients was explained by these factors.
3. Results
A total of 3557 patients were registered and followed up be-
tween 1 January 1980 and 31 December 2015. We excluded 2 pa-
tients whose vital status was unknown and 2 patients aged more
than 80 years at registration. The resulting cohort of 3553 patients
was followed for 67,760 person years with a median duration of
follow up of 20 years. As shown in Supplementary Table 1 it con-
sisted of 1724 Male and 1829 female patients, and as shown in
Supplementary Table 2, of these 1903 had a diagnosis of SB DFH and
1650 of PFH. At registration, 27% of men and 18.7% of women had
known CHD (Supplementary Table 1) deﬁned as either a history of a
previous myocardial infarction, angina, a coronary artery by-pass
graft, or angioplasty, but history of CHD was not signiﬁcantly
different between DFH and PFH patients (Supplementary Table 2).
As expected, those with DFH had signiﬁcantly higher total and LDL-
C and lower HDL-C than PFH patients who had higher systolic and
diastolic blood pressure, a higher rate of smoking and BMI, and a
higher prevalence of type 2 diabetes. Before treatment the mean
total cholesterol concentration was on average 0.68mmol/l and
LDL-C 1.01mmol/l higher in DFH compared to PFH subjects (both
p< 0.001).
Table 1 shows the observed and expected number of deaths by
major cause and time period. In total, there were 585 deaths from
all causes and 252 from CHD. As shown in Table 2, within the FH
sample studied riskwas independently related to age, sex, smoking,
previous CHD, total cholesterol and DFH/PFH. Overall, the hazard
ratio for DFH vs PFH is 1.37 (1.07e1.77) p¼0.013 before adjustment
Table 1
Observed and expected deaths by major cause and time period in DFH þ PFH patients all ages.
From 1 January 1980 to 31 December 1991 Person-years
exposure¼ 6627 years
From 1 January 1992 to December 2008 Person-years
exposure¼ 43,117 years
Observed Expected SMR 95% CI p-value Observed Expected SMR 95% CI p-value
Coronary heart disease 36 11.30 319 (223, 441) <0.0001 162 79.40 204 (174, 238) <0.0001
Stroke 1 2.91 34 (1, 192) 0.43 21 27.73 76 (47, 116) 0.23
Accidents & violence 1 2.22 45 (1, 251) 0.70 6 9.98 60 (22, 131) 0.26
All cancers 14 14.71 95 (52, 160) 0.99 91 140.53 65 (52, 80) <0.0001
All-causes of death 54 40.49 133 (100, 174) 0.05 356 385.05 92 (83, 103) 0.14
From 1 January 2009 to 31 December 2015 Person-years exposure¼ 17,317 years p-value trend
Observed Expected SMR 95% CI p-value
Coronary heart disease 54 23.23 232 (175, 303) <0.0001 0.31
Stroke 6 9.19 65 (24, 142) 0.38 0.77
Accidents & violence 1 2.47 40 (1, 225) 0.58 1.00
All cancers 56 60.69 92 (70, 120) 0.60 0.26
All-causes of death 175 153.08 114 (98, 133) 0.09 0.61
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the stepwise model. The ten year CHDmortality rate (Kaplan-Meier
estimate) for those without CHD at baseline is 1.2% and for those
with prior CHD it is 10.7%. After adjusting for age this equates to a
rate of 0.8% at age 40, 1.4% at age 50 and 2.6% at age 60 for those
without prior CHD, with rates in those with prior CHD being 7.2%,
9.4% and 12.4% respectively.
Separate analyses for mortality were undertaken for the time
period before January 1992, when statins were not routinely used,
between January 1992eDecember 2008, during which time statin
treatment became widely available, and from 2009 to December
2015, when it would be expected that FH patients would have their
LDL-C levels managed with high potency statin treatment and or
combination therapy with other lipid lowering agents such as
ezetimibe. As shown in Table 1, there was signiﬁcant excess coro-
nary mortality for all three periods, falling a 3.19-fold excess
(2.23e4.41) to 2.04 (1.74e2.38) to 2.32 (1.75e3.03). There was a
signiﬁcant excess mortality from all causes before, but not after, 1
January 1992, due mainly to a lower SMR for cancer.
We next compared the CHD SMR (95% CI) in statin treated
Simon Broome deﬁned DFH and PFH. As shown in Table 3, the CHD
SMR was higher at all times in DFH compared to PFH patients, and
using the combined data post 1991 for 1903 DFH patients (149
events in 36,625 person years follow-up) compared to1650 PFH
patients (103 events, 30,435 person years follow-up), the 2.4-fold
excess coronary mortality in treated DFH was signiﬁcantly higher
than the 1.78 excess in PFH (35%, 95% CI 3e76%, p¼ 0.03)). We also
compared the CHD SMR using the Simon Broome and DLCN score
system. As shown in Supplementary Fig. 1, there was no signiﬁcant
difference in the excess coronary mortality between SB DFH pa-
tients and DLCN Deﬁnite FH (ie score >8) (2.53 (2.14e2.97) vs. 2.53Table 2
Univariate and multivariate factors associated with CHD mortality in DFH plus PFH patie
Variable Univariate associations with CHD
death
HR (95% CI) p value
Age (years) Per 10years 1.87 (1.57e2.21) <0.0001
Sex F:M 0.45 (0.34e0.58) <0.0001
Ever smoker Y:N 1.96 (1.51e2.54) <0.0001
Diabetes Y:N 2.03 (1.00e4.10) 0.05
Total cholesterol (mmol/l) Per SD 1.37 (1.23e1.52) <0.0001
BMI (kg/m2) Per SD 1.12 (0.97e1.30) 0.128
SBP (mmHg) Per SD 1.09 (0.96e1.25) 0.198
Prior CHD Y:N 5.76 (4.38e7.57) <0.0001
Diagnosis DFH:PFH 1.37 (1.07e1.77) p¼ 0.013(2.07e2.05)) and in PFH and DLCN <8 (1.85 (1.51e2.24) vs. 1.65
(1.30e2.06)).
Since we now know that the majority of DFH patients have a
detectable monogenic cause for their FH phenotype, while the
majority of PFH patients have a polygenic cause [15], the remainder
of the analysis are restricted to only the DFH patients, in order to
obtain estimates of the CHD mortality in treated monogenic FH
patients. Also, because our previous analysis showed higher CHD
SMR in those with existing CHD on registration [9,16], data are
shown in those with CHD at registration (i.e. where statin treat-
ment is secondary prevention) and those with no CHD at regis-
tration (i.e. primary prevention). Data are presented in Table 4 and
Fig. 1A and B, with a breakdown of SMR by age group in
Supplementary Table 4. In treated DFH patients with previous CHD
the CHD SMR was signiﬁcantly elevated at all time periods but in
men fell from a 4.83-fold excess (2.32e8.89) pre-1992 to 4.66
(3.46e6.14) in 1992e2008 and 2.51 (1.01e5.17) post 2008, repre-
senting a 48% fall overall. By contrast, in women these values were
7.23 (2.65e15.73), 4.42 (2.70e6.82) and 6.34 (2.06e14.81)). In
treated DFH men with no previous CHD the excess coronary mor-
tality fell over the three time periods (55% overall), and was not
signiﬁcantly elevated post-2008 (0.89 (0.29e2.08), but inwomen it
remained signiﬁcantly elevated (post-2008 3.65 (1.75e6.72)).
These later values need to be interpreted with caution because of
the small number of person years follow up, and low number of
events, for example in the last time period for primary prevention
in women there were 5 events observed and less than 1 expected,
and in secondary prevention there were 10 events observed
compared to less than 3 expected.
Because the SMR calculation is based on a comparison of the
mortality rate in FH patients versus the general population, thents combined.
Multivariable model including
all variables
Model selected using stepwise
Cox regression
HR (95% CI) p value HR (95% CI) p value
1.49 (1.21e1.83) 0.0001 1.52 (1.26e1.82) <0.0001
0.48 (0.35e0.65) <0.0001 0.49 (0.37e0.64) <0.0001
1.70 (1.26e2.30) 0.0005 1.60 (1.22e2.10) 0.001
1.91 (0.70e5.19) 0.207
1.39 (1.24e1.56) <0.0001 1.40 (1.26e1.55) <0.0001
1.08 (0.89e1.30) 0.441
1.07 (0.92e1.25) 0.381
4.19 (3.05e5.74) <0.0001 4.33 (3.24e5.80) <0.0001
1.32 (0.98e1.77) 0.072
Table 3
Observed and expected CHD and Total deaths by time period in DFH vs PFH patients (all ages).
Total Pyrs From 1 January 1980 to 31 December 1991 Total Pyrs From 1 January 1992 to December 2008
Observed Expected SMR 95% CI p-value Observed Expected SMR 95% CI p-value
DFH patients
Coronary heart disease 3887 24 6.72 357 (229, 531) <0.0001 23,278 98 39.96 245 (199, 299) <0.0001
All cause of death 3887 37 23.69 156 (110, 215) 0.01 23,278 194 192.77 100 (87,116) 0.95
PFH patients
Coronary heart disease 2740 12 4.58 262 (135, 458) 0.0005 19,839 64 39.44 162 (125, 207) 0.0004
All-causes of death 2740 17 16.80 101 (59, 162) 1.00 19,839 162 192.28 84 (72, 98) 0.03
Total Pyrsa From 1 January 2009 to 31 December 2015 p-value trend
Observed Expected SMR 95% CI p-value
DFH patients
Coronary heart disease 9460 27 11.92 227 (149, 330) 0.0002 0.16
All-causes of death 9460 84 78.66 107 (85, 132) 0.0.58 0.25
PFH patients
Coronary heart disease 7857 27 11.31 239 (157, 347) 0.0001 0.70
All-causes of death 7857 91 74.42 122 (98, 150) 0.07 0.02
a Pys¼ person years exposure.
Table 4
Observed and expected CHD deaths by time period in DFH males and females (all ages) with and without CHD at registration.
Total Pyrs From 1 January 1980 to 31 December 1991 Total Pyrs From 1 January 1992 to December 2008
Observed Expected SMR 95% CI p-value Observed Expected SMR 95% CI p-value
Male patients
CHD 616 10 2.07 483 (232, 589) 0.0001 2940 50 10.7 466 (346, 614) <0.0001
No CHD 1444 5 2.53 197 (64, 460) 023 8557 17 14.28 119 (69, 191) 0.54
Female patients
CHD 417 6 0.83 723 (265, 1573) 0.0004 1948 20 4.53 442 (270, 682) <0.0001
No CHD 1410 3 1.29 233 (48, 681) 0.28 9832 11 10.4 105 (53, 189) 0.94
Total Pyrs From 1 January 2009 to 31 December 2015 p-value trend
Observed Expected SMR 95% CI p-value
Male patients
CHD 975 7 2.79 251 (101, 517) 0.035 0.11
No CHD 3823 5 5.6 89 (29, 208) 0.99 0.27
Female patients
CHD 535 4 0.77 516 (141, 1323) 0.016 0.50
No CHD 4127 10 2.74 366 (165, 672) 0.001 0.16
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mortality rates in the general population. To examine this we ob-
tained estimates of the CHD mortality rates for men and women in
England andWales, which show that in the general population CHD
mortality fell by 21% inmales and by 25% in females over the period
examined (Supplementary Fig. 2). By contrast, mortality rates in
treated DFH patients fell by 60% in males but only by 25% in fe-
males. This suggests that the high SMR post-2008 in women with
FH is not explained by a disproportionally large fall in the CHD rate
in the general population.
Finally we estimated the SMR for different types of cancer, to
examine whether the previously reported lower risk for cancer
mortality in treated FH patients on the register is maintained in
extended follow-up. As shown in Table 4 post 1991, the risk of fatal
cancer (17,317 person years exposure) was signiﬁcantly lower than
in the general population (0.70 (0.59e0.83)), mainly due to lower
rates of respiratory and lymphatic cancer deaths.
4. Discussion
The main new ﬁnding of this follow up analysis of the Simon
Broome FH registry participants, with over 67,000 person-years
and 585 deaths, including 252 from CHD, is that whilst the risk offatal coronary disease has continued to fall with treatment in men
with FH over the three time-periods examined, there has not been a
corresponding reduction among women. In DFH men with pre-
existing CHD, there was a progressive 48% decrease in CHD SMR
from the pre-statin period before 1991, compared to the latest
period examined between 2009 and 16. By comparison, in the
corresponding group of women with DFH, coronary mortality was
similar before and after the introduction of statins. While this could
be an artefact due to the relatively small number of events and
person years follow up in this later period, it is striking that a
similar pattern is observed in both the primary and secondary
prevention analyses. This raises the question of whether these DFH
women are being treated as rigorously as their male counterparts.
For example statin treatment may not be initiated as early as in
men, or with statins as potent or in doses to achieve as low ther-
apeutic LDL targets. However, while the overall death rate in this
group of treated DFH patients is 20.1 per 1000 person years (315/
15674), the CHD death rate is only 9.5/1000 person years (149/
15674). This means that, in this group of patients, CHD is the cause
of death in only 44% of cases, again supporting the utility of statin
treatment in preventing CHD in patients with FH.
Those subjects whowere recruited before 1992were not treated
with statins at registration, thus allowing us to estimate the FH CHD
Fig. 1. SMR CHD deaths for DFH patients age 20e79 years with and without previous
CHD.
(A) In 940 DFH men, (B) in 963 DFH women.
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available at the time of registration were low potency, or, if avail-
able, high potency statins were often not prescribed because
treatment targets at that time were relatively conservative, in part
reﬂecting initial uncertainty about potential long-term safety. This
allows us to estimate changes in CHD SMR in the “low” statin era,
compared to that when high intensity statins became available. At
registration 42.7% of DFH and 46.2% of PFH patients were on statin
treatment and showed a similar (p¼0.24) 17.5% and 19.5% reduction
of LDL-C levels from untreated values. We do not have follow up
lipid level data in the Simon Broome registrants, but the inference
we have made is that the FH patients on the register have, over
time, had their statin therapy up-titrated in line with statin avail-
ability andwith regard to changing CHD guidelines. Data on current
treatment of FH patients comes from the UK 2010 National FH
Survey data [21], where 86% of patients were reported to be treated
with either atorvastatin or rosuvastatin, and 40% were also on
ezetimibe. Mean (SD) untreated LDL-C was 6.44 (1.77) mmol/l, and
by the third clinic visit this had been lowered to a mean of 3.60
(1.48) mmol/l, representing an overall median reduction of 47%
(IQR 28%e59%) from baseline (Supplementary Fig. 3). and it is
reasonable to assume that the Register patients would be similarly
treated. However, in the 2010 survey, while 52% of men with CHD
achieved a 50% or more reduction in baseline LDL-C only 47% of
women with CHD reached this target (p¼ 0.04), supporting the
view that women with CHD are being less effectively treated than
men (Supplementary Fig. 4). Several reports have been publishedrecently indicating that women are undertreated with statins
[22,23]. In the CASCADE-FH study from the US, compared to men
with FH, womenwith FH were 40% less likely to recive a statin, 32%
less likely to achieve the recommended target LDL-C and 21% less
likely to achieve 50% LDL-C lowering [22]. Furthermore, in a recent
UK general population study, overall womenwere 24% less likely to
initiate or maintain statin therapy compared to men [23].
Using the enlarged data set, we were able to conﬁrm several of
our earlier ﬁndings. As reported [19], in those with a clinical
diagnosis of Deﬁnite FH, the SMR was 35% higher in the post 1991
period compared to those with Possible FH. Overall, CHD risk was
independently related to age, sex, smoking, previous CHD and total
cholesterol, but after adjustment for these variables the higher CHD
risk in DFH compared to PFH patients was no longer statistically
signiﬁcant. Since we know that up to 80% of those with clinical DFH
will carry an FH-causing mutation [13,14] while probably 80% of
those with clinical PFH have a polygenic aetiology of their hyper-
lipidaemia [15,16], this conﬁrms reports that carriage of an FH
mutation is associated with greater CHD risk [4]. This higher risk is
supported by the observation that, even though LDL-C levels were
similar, compared to those with polygenic hypercholesterolaemia,
those with an FH-causing mutation have greater carotid intimal-
medial thickening and coronary calciﬁcation [24]. As previously
reported [8,9], the CHD SMR in younger FH patients was extremely
high, and Supplementary Table 4 shows that although the absolute
event rate in patients aged 20e39 was low at all time periods, the
CHD SMR in the DFH men and women with no previous CHD fell
pre 1992 from 3750 (773e10959) to 1153 (238e3372) in
1992e2008, but was 5601 (678e20233) post 2008.
Since many recent guidelines for the management of FH [1]
recommend use of the DLCN score for the diagnosis of FH, we
compared the CHD SMR of those with Simon Broome DFH and PFH
with the DLCN score equivalent groups (Score >8 and 5e8
respectively). The data shows that these two diagnostic criteria are
equally good at distinguishing those with clinical FH who have a
higher or lower CHD risk.
We were able to conﬁrm our earlier report [18] that in DFH
patients who did not have CHD at registration, the CHD SMR in the
post-statin period is not greater than the general population, sup-
porting the signiﬁcant clinical utility of identifying subjects with FH
before they have developed CHD and ensuring they receive inten-
sive lipid-lowering therapy. We were also able to conﬁrm [18] the
ﬁndings that this cohort of FH patients continue to show lower
mortality rates of particularly smoking-related cancers, due most
likely to the lower rate of smoking and other positive life-style
changes recommended for these patents during their ongoing
care by lipid clinics. Data from the Health Survey for England
(https://digital.nhs.uk), show that in 1993, 28% of men and 26% of
women in the UK self-reported as smokers, but by 2016 these ﬁg-
ures had fallen to 20% and 16% respectively. This compares with a
lower smoking prevalence at registration of 16.8% in the FH men
and 19.8% inwomen, while in the 2010 FH audit [21] the prevalence
was 14%. The lower cancer mortality seen may also, in part, be
because of earlier detection and treatment of cancer among pa-
tients undergoing regular medical surveillance, resulting in a better
prognosis. We cannot, however, entirely exclude the possibility that
statins have anti-cancer activity, although a meta-analysis of 27
randomised trials of statin therapy over a relatively short period of
about ﬁve years showed no difference in the incidence or mortality
from cancers [25].
4.1. Strengths and limitations
There are a number of strengths of the current study. Follow-up
of the cohort is essentially complete, with an observation period
S.E. Humphries et al. / Atherosclerosis 274 (2018) 41e4646now including more than 67,000 patient years, with an increase in
the duration of follow up of 45% since the 2008 analysis. Our study
is one of the largest long-term data sets available with only that in
Holland being larger. The SMRs are relevant for estimating the
mortality in untreated and treated FH patients in the UK and can
robustly inform health economic modelling, as has been done
recently [25,26]. We have no information on deaths since 2016
which might be used to strengthen our data. The Register only has
information on registration levels of lipids and historical on-
treatment lipids, but does not have recent on-treatment lipid
data so we cannot say with certainty what current treatment or
LDL-C levels are in any of the subjects. At the time of the UK 2010
National Survey, most FH patients were reported to be treated with
either atorvastatin or rosuvastatin, 40% were also on ezetimibe, and
it is reasonable to assume that the Register patients would be
similarly treated. The major limitations are due to the relatively
small number of deaths occurring in the latest period between
2008 and 2016. In the whole cohort this includes more than 17,000
person years and 54 CHD deaths, but in the DFHmenwith CHD this
is 975 person years and 7 events observed (2.8 expected), while in
the DFH women this is 535 person years with 4 events observed
(0.8 expected). Because of this, the conﬁdence intervals are large
and the point estimates need to be interpreted cautiously.
In conclusion, these data conﬁrm the beneﬁt of statin treatment
in reducing CHD mortality in patients with a clinical diagnosis of
FH, but suggest that, despite recent European [1] and UK guidelines
recommending the use of potent statins to lower LDL-C, FH patients
with pre-existing CHD, and a proportion of women with FH, may
not be treated adequately. Because of their high CHD risk, patients
with FH cannot be recruited into a randomised-controlled trial of
placebo versus lipid lowering therapy, but long-term follow-up
registers such as used here, and the Familial Hypercholesterolaemia
Studies Collaboration [26] can provide valuable data to examine the
utility of statin treatment.
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